Patents Assigned to Applied Research Systems ARS Holding N.V.
  • Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (LAG-3)
    Patent number: 6500422
    Abstract: A method to prevent graft rejection of transplanted cells, tissues or organs without general immunosuppression is described. The method employs a newly discovered protein, LAG-3. When allogeneic or xenogeneic cells are engineered to express LAG-3 on their surface and transplanted, immune destruction of the implanted cell, tissue or organ is prevented, while the host's immune system remains functional. A particular application of this method allows the preparation of a universal gene therapy host cell expressing LAG-3 on its surface for protection from graft rejection by a host's immune system.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: December 31, 2002
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Mauro Biffoni, Ruben Papoian
  • PEG-LHRH analog conjugates
    Publication number: 20020183257
    Abstract: PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog either directly or via a bifunctional linker molecule, such as an amino acid, and methods for producing these conjugates are provided in the present invention. Also provided are a pharmaceutical composition and a method for treating pathologies in which LHRH analog administration is beneficial.
    Type: Application
    Filed: June 28, 2002
    Publication date: December 5, 2002
    Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
    Inventors: Nabil El-Tayar, Xuan Zhao, Michael D. Bentley
  • Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants
    Patent number: 6482925
    Abstract: The invention concerns a purified polypeptide corresponding to a mutated form of the soluble LAG-3 protein or of one of its fragments comprising the extra-cellular domain D1 and D2.
    Type: Grant
    Filed: January 6, 2000
    Date of Patent: November 19, 2002
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Nabil El Tayar, Bertrand Huard, Renato Mastrangeli, Frederic Triebel
  • Method for producing a heterologous secreted protein from chinese hamster ovary cells grown on microcarriers
    Patent number: 6458565
    Abstract: The present invention relates to a method for producing a heterologous secreted protein from transformed CHO cells grown on microcarriers in a serum-free cell culture medium. This method avoids a production lag phase when switching from a serum-containing to a serum-free environment, a problem observed in the mammalian adherent cell culture production of secreted proteins.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: October 1, 2002
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Mark Cunningham, Tom Iley
  • Medicaments for initiating ovulation
    Publication number: 20020136774
    Abstract: The invention relates to medicaments for initiating ovulation comprising LH in an administrable form which ensures an increase in LH plasma levels for a period of some 40 to 60 hours.
    Type: Application
    Filed: May 9, 2002
    Publication date: September 26, 2002
    Applicant: Applied Research System ARS Holding N.V.
    Inventor: Jean-Claude Emperaire
  • CD16-II variants
    Patent number: 6444789
    Abstract: Human CD16-II variants, DNA sequences coding for them, their use in therapy and/or in diagnosis of autoimmune diseases and inflammatory illnesses, as well as pharmaceutical compositions comprising them, are disclosed. The sequence listing for the new polypeptides is provided.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: September 3, 2002
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventor: Shun Luo
  • HCG and derivatives as matrix metalloproteases inhibitors
    Patent number: 6444639
    Abstract: The use of hCG, hCG &bgr;-subunit, as well as fragments and active derivatives thereof, or hCG &bgr;-core in the preparation of a medicament for the prophylaxis and/or the treatment of pathologies requiring inhibition of the matrix metalloprotease (MMP) enzymatic activity.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: September 3, 2002
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Adriana Albini, Giorgia Orengo
  • PEG-LHRH analog conjugates
    Patent number: 6433135
    Abstract: PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog either directly or via a bifunctional linker molecule, such as an amino acid, and methods for producing these conjugates are provided in the present invention. Also provided are a pharmaceutical composition and a method for treating pathologies in which LHRH analog administration is beneficial.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: August 13, 2002
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Nabil El-Tayar, Xuan Zhao, Michael D. Bentley
  • Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment
    Patent number: 6410509
    Abstract: The present invention concerns the use of a MHC class II ligand, LAG-3, for the manufacture of a medicament for preventing or treating pathological conditions involving an antigen specific immune response, as well as the use of LAG-3 in cancer immunotherapy. The invention also concerns a pharmaceutical composition comprising an effective amount of an antigen together with an effective amount of human LAG-3, wherein LAG-3 s present as an adjuvant.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: June 25, 2002
    Assignees: Institut Gustave-Roussy, Applied Research Systems ARS Holding N.V.
    Inventor: Frederic Triebel
  • Ovulation triggering drugs
    Patent number: 6407057
    Abstract: The invention relates to medicaments for initiating ovulation comprising LH in an administrable form which ensures an increase in LH plasma levels for a period of some 40 to 60 hours.
    Type: Grant
    Filed: December 9, 1997
    Date of Patent: June 18, 2002
    Assignee: Applied Research System ARS Holding N.V.
    Inventor: Jean-Claude Emperaire
  • Reconstituting device for injectable medication
    Publication number: 20020068896
    Abstract: A device for reconstituting liquid for medical use by bringing together a first liquid medium contained in a first vessel in the form of a cartridge (3) and a second medium, such as a drug in solid form, contained in a second vessel in the form of a vial (7), the device (19) comprising means (41) for supporting the first and second vessels, and a movable operating member (50) for applying a force to cause the first liquid medium to be delivered at a controlled rate from the first vessel into the second vessel. The first and second vessels may be provided in a pack (70) having liquid transfer means in the form of a needle (10).
    Type: Application
    Filed: December 10, 2001
    Publication date: June 6, 2002
    Applicant: Applied Research Systems ARS Holding N.V.
    Inventors: Grenville Arthur Robinson, Michael Anthony Hobbs, Martyn Omar Rowlands, John Richard Calvert
  • Ice inhibiting peptides
    Patent number: 6380162
    Abstract: The present invention relates to a peptide capable of binding to ICE and/or to enzymes of the ICE family, which peptide consists essentially of the amino acid sequence of SEQ ID NO:1 reported in the Sequence Listing, in which Xaa is selected between Asp and Ala, optionally containing one or more amino acids at its N-terminal and/or C-terminal end. It also relates to the use of the above peptide, for the preparation of pharmaceutical compositions active in pathologies requiring ICE inhibition and/or inhibition of enzymes of the ICE family.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: April 30, 2002
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Marta Muzio, Martino Introna, Alberto Mantovani
  • IFNAR2/IFN complex
    Patent number: 6372207
    Abstract: The in vivo effect of Type I interferon (IFN) can be prolonged by administering the interferon in the form of a complex with an IFN binding chain of the human interferon &agr;/&bgr; receptor (IFNAR). Such a complex also improves the stability of the IFN and enhances the potency of the IFN. The complex may be a non-covalent complex or one in which the IFN and the IFNAR are bound by a covalent bond or a peptide. When bound by a peptide bond in the form of a fusion protein, the IFN may be separated from the IFNAR by means of a peptide linker. Such a fusion protein may be produced by recombinant DNA technology. Storing IFN in the form of such a complex improves the storage life of the IFN and permits storage under milder conditions than would otherwise be possible.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: April 16, 2002
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Mark Tepper, Mark Cunningham, David Sherris, Nabil El Tayar, Sean McKenna
  • Methods for assaying human FSH using human FSH receptor
    Patent number: 6372711
    Abstract: The present invention embraces essentially pure human FSH receptor, or a fragment or mutant thereof which binds FSH, DNA encoding said receptor, fragment or mutant, expression vectors comprising said DNA, cells transfected with said expression vectors, and methods of producing said receptor, fragment or mutant by culturing said transfected cells. The present invention also includes pharmaceutical compositions comprising said receptor, fragment or mutant, as well as methods of treating patients with such compositions to reduce endogenous FSH bioactivity. An improved assay for human FSH using the receptor, fragment or mutant of the present invention is also disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 16, 2002
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Christie Ann Kelton, Shirley Vui Yen Cheng, Noreen Patrice Nugent, Rene Lynn Schweickhardt
  • Allelic variant of human STAT3
    Patent number: 6369198
    Abstract: An allelic variant of the human STAT3 protein and compositions comprising it are disclosed.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: April 9, 2002
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Ottaviano Serlupi-Crescenzi, Linda Della Pietra
  • Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans
    Patent number: 6348444
    Abstract: The invention relates to the use of human growth hormone for the manufacture of a medicament for stimulating hematopoiesis and immune reconstitution to be administered to a patient in need thereof about 30 days post-transplantation of hematopoietic stem cells.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: February 19, 2002
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventor: Scott C. Chappel
  • Pharmaceutical compositions thereof, and methods of using same
    Patent number: 6337316
    Abstract: The present invention relates to peptidomimetics capable of inhibiting CD28 and/or CTLA-4 interaction with CD80 (B7-1) and CD86 (B7-2) and having a core amino acid sequence, LeuMetTyrProProProTyrTyr, corresponding to residues 2 to 9 of SEQ ID NO:1. The present invention also relates to pharmaceutical compositions and a method of treating pathologies and disorders which are improved by inhibition of CD28 and/or CTLA-4 interaction with CD80 and CD86.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: January 8, 2002
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Nabil El Tayar, Steven Blechner, Brad Jameson, Mark Tepper
  • Benzo[c]quinolizine derivatives, their preparation and use as 5&agr;-reductases inhibitors
    Patent number: 6303622
    Abstract: The present invention refers to benzo[c]quinolizine derivatives of general formula (I) their pharmaceutically acceptable salts or esters, processes for their preparation and pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 29, 1998
    Date of Patent: October 16, 2001
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Antonio Guarna, Mario Serio
  • Human FC&ggr; receptor III
    Patent number: 6294347
    Abstract: Soluble and membrane-bound forms of human Fc&ggr;RIII are provided, together with nucleic acids capable of encoding the same. Soluble Fc&ggr;RIIIs are useful in ameliorating the serum platelet deficiency associated with immune thrombocytopenic prupura. Cells expressing membrane-bound Fc&ggr;RIIIs are useful components in assays for serum immune complexes.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: September 25, 2001
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Gary A. Peltz, Kevin W. Moore
  • Compounds that inhibit the binding of RAF-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same
    Patent number: 6281193
    Abstract: The invention relates to compounds, such as proteins, peptides and organic compounds, capable of blocking or inhibiting the binding interaction of Raf-1 or 14-3-3 proteins to the &bgr; chain of IL-2, and pharmaceutical compositions containing such compounds. In vitro assays for isolating, identifying and characterizing such compound capable of inhibiting interaction of Raf-1 or 14-3-3 proteins to IL-2&bgr; are also provided.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: August 28, 2001
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Terry Strom, Wlodzimierz Maslinski